An Open-label, Multi-center Phase Ib/II Study of CN201 in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia
An effective treatment for adults and children B-ALL represents a significant unmet need. CN201 has demonstrated efficacy in nonclinical models of leukemia .CN201 has a longer half-life, thus long term continuous intravenous infusion is not necessary for clinical use. The present study will be conducted in 2 parts: Phase Ib is a dose finding phase to identify the RP2D. Phase II will allow further evaluation of the safety and efficacy of CN201 at the RP2D.
A Single-Arm, Open-Label, Dose Escalation Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This study aims to provide a basis for further clinical development of CN201.
100 Clinical Results associated with Curon Biopharmaceutical (Hong Kong) Ltd.
0 Patents (Medical) associated with Curon Biopharmaceutical (Hong Kong) Ltd.
100 Deals associated with Curon Biopharmaceutical (Hong Kong) Ltd.
100 Translational Medicine associated with Curon Biopharmaceutical (Hong Kong) Ltd.